The White House has officially withdrawn the nomination of Dr. Heidi Overton as the next commissioner of the Food and Drug Administration (FDA), a senior administration official and others familiar with the decision confirmed. Axios initially reported that the move was made after the Senate health committee had scheduled a vote on her nomination for Wednesday.
President Trump had nominated Overton, a physician and White House domestic policy staffer, earlier in the summer. However, she faced significant challenges in securing support among Senate Republicans. Critics expressed skepticism regarding her public testimony on the FDA-approved abortion drug mifepristone and her role in implementing presidential policies favoring vape products.
Although outgoing Senate Health, Education, Labor and Pensions Committee Chair Bill Cassidy of Louisiana told CBS News late Tuesday that a pathway for the nomination to advance still existed, whip counts had not yet secured the necessary votes. The decision to withdraw the nomination was communicated by the White House late Tuesday evening, while efforts to gather support were still ongoing.
Overton was closely associated with former White House Chief of Staff Susie Wiles, who recently departed her position. With the withdrawal, the FDA remains under the leadership of Acting Commissioner Kyle Diamantas. Sources indicate that the administration has begun exploring alternative candidates for the role, including potential acting nominees who would bypass the Senate confirmation process.
One candidate mentioned by two sources is Senator Roger Marshall of Kansas, a physician who recently lost his reelection bid to Democrat Adam Hamilton. Any permanent commissioner confirmed by the Senate would likely need to be finalized before Democrats gain control of the House in January. Sen. Cassidy noted the dilemma of choosing between short-term administrators and a permanent official, stating that the goal is to find someone who can establish independence within the remaining time window.
Honestly, this whole situation feels like a chaotic mess. I just hope patient safety is not compromised here.
The FDA needs a real commissioner, not just another acting placeholder who will last six months before leaving.
Surprised Senator Marshall is being considered after losing his election. That seems like a strange political move honestly.
I wonder if they will actually bypass the Senate confirmation process or if that legal maneuver will fail?
It is shocking how quickly they dropped her just because a few Republicans had doubts about her testimony.